findings show miRNA-130a expression is increased in nonsmall cell lung cancer tissues; overexpression of miRNA-130a was strongly associated with lymph node metastasis, stage of tumor node metastasis classification and poor prognosis

Data show that showed that miR-130a, expressed at low level in lung cancer cell lines, by targeting MET was able to reduce TRAIL resistance in non-small cell lung cancer (NSCLC) cells through the c-Jun-mediated downregulation of miR-221 and miR-222.

miR-130a is over-expressed in gefitinib- sensitive NSCLC cell lines, but is low in gefitinib-resistant Non-small cell lung cancer cell lines. miR-130a/Met axis plays an important role in gefitinib resistance in Non-small cell lung cancer.

In non-small cell lung cancer patients, the results showed that miR-130a downregulation exhibited clinical relevance as it was correlated with poor prognosis and increased tumor stage and metastasis

CCAT1/miR-130a-3p axis enhanced cisplatin resistance of non-small-cell lung cancer (NSCLC) cells by targeting SOX4, providing potential targets to overcome cisplatin resistance and improve efficacy of chemotherapy for patients with NSCLC

MicroRNA-130-5p promotes invasion as well as migration of lung adenocarcinoma cells by targeting the EZH2 signaling pathway.

MicroRNA-130a enhances the killing ability of natural killer cells against non-small cell lung cancer cells by targeting signal transducers and activators of transcription 3.

MicroRNA-130a targeting hypoxia-inducible factor 1 alpha suppresses cell metastasis and Warburg effect of non-small cell lung cancer cells under hypoxia.

The microRNA-130a-5p/RUNX2/STK32A network modulates tumor invasive and metastatic potential in non-small cell lung cancer.